ACVR2B: A Promising Drug Target and Biomarker for Various Diseases

Target Name: ACVR2B

NCBI ID: G93

ACVR2B

ACVR2B: A Promising Drug Target and Biomarker for Various Diseases

The ACVR2B (Activin A receptor type IIB) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the activin receptor family, which includes proteins that are involved in the regulation of cell growth, differentiation, and survival.

The ACVR2B protein is known for its role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It is also potential drug target and biomarker.

ACVR2B in Cancer

Cancer is a leading cause of death worldwide, and its development and progression are closely related to the regulation of cell growth and survival. The ACVR2B protein plays a crucial role in these processes by regulating the growth and survival of cancer cells.

Studies have shown that ACVR2B is involved in the regulation of cell proliferation, migration, and invasion. It has been shown to promote the growth and survival of various cancer cell types, including breast, ovarian, and colorectal cancer.

In addition, ACVR2B has also been shown to contribute to the development of resistance to chemotherapy in cancer cells. This is because ACVR2B helps cancer cells to survive the harsh effects of chemotherapy by regulating the production of energy from the inside out.

ACVR2B in Neurodegenerative Diseases

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neuroplasticity. The ACVR2B protein is involved in the regulation of these processes.

Studies have shown that ACVR2B is involved in the regulation of neurogenesis, which is the process by which new neurons are produced in the brain. Additionally, ACVR2B has been shown to play a role in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time.

ACVR2B in Autoimmune Disorders

Autoimmune disorders, such as rheumatoid arthritis, lupus, and multiple sclerosis, are characterized by the immune system attacking the body's own tissues. The ACVR2B protein is involved in the regulation of these processes.

Studies have shown that ACVR2B is involved in the regulation of immune cell function and the production of autoantibodies. Additionally, ACVR2B has been shown to contribute to the regulation of inflammation and the production of pro-inflammatory cytokines.

ACVR2B as a Drug Target

The ACVR2B protein is a potential drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The ACVR2B protein is a good candidate for a drug because of its unique structure and its involvement in multiple cellular processes that are important for the development and progression of these diseases.

ACVR2B has been shown to be a potent inhibitor of cancer cell growth and has the potential to be used as a cancer therapeutic. Additionally, ACVR2B has also been shown to be a potential treatment for neurodegenerative diseases by increasing the production of neurogenesis and increasing the production of brain-resident immune cells.

ACVR2B has also been shown to be a potential treatment for autoimmune disorders by reducing the production of pro-inflammatory cytokines and increasing the production of anti-inflammatory cytokines.

Conclusion

The ACVR2B protein is a unique and promising drug target for the treatment of various diseases. Its involvement in the regulation of cell growth, differentiation, and survival makes it a promising candidate for the development of new therapeutic agents.

Furthermore, the ACVR2B protein is also a biomarker that can be used to diagnose and monitor the progression of various diseases.

It is important to note that while ACVR2B is a promising drug target and biomarker, more research is needed to fully understand its role and its potential as a therapeutic agent.

Protein Name: Activin A Receptor Type 2B

Functions: Transmembrane serine/threonine kinase activin type-2 receptor forming an activin receptor complex with activin type-1 serine/threonine kinase receptors (ACVR1, ACVR1B or ACVR1c). Transduces the activin signal from the cell surface to the cytoplasm and is thus regulating many physiological and pathological processes including neuronal differentiation and neuronal survival, hair follicle development and cycling, FSH production by the pituitary gland, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. Activin is also thought to have a paracrine or autocrine role in follicular development in the ovary. Within the receptor complex, the type-2 receptors act as a primary activin receptors (binds activin-A/INHBA, activin-B/INHBB as well as inhibin-A/INHA-INHBA). The type-1 receptors like ACVR1B act as downstream transducers of activin signals. Activin binds to type-2 receptor at the plasma membrane and activates its serine-threonine kinase. The activated receptor type-2 then phosphorylates and activates the type-1 receptor. Once activated, the type-1 receptor binds and phosphorylates the SMAD proteins SMAD2 and SMAD3, on serine residues of the C-terminal tail. Soon after their association with the activin receptor and subsequent phosphorylation, SMAD2 and SMAD3 are released into the cytoplasm where they interact with the common partner SMAD4. This SMAD complex translocates into the nucleus where it mediates activin-induced transcription. Inhibitory SMAD7, which is recruited to ACVR1B through FKBP1A, can prevent the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. Activin signal transduction is also antagonized by the binding to the receptor of inhibin-B via the IGSF1 inhibin coreceptor

The "ACVR2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACVR2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets